what is oral semaglutide shows promising results for type 2 diabetes in routine clinical settings Oral Semaglutide Vs Injectable –
Description
Retatrutide acts as a triple agonist on GLP-1, GIP, and glucagon receptors
As of April 2026, two trials have read out and seven more are expected to report through the year, with NDA filing targeted for Q4 2026
Each unit contains 0.025 mg of semaglutide
Summer also tends to be when motivation is highest and results feel most rewarding
